| Document |
Document Title |
|
WO/2003/100097A1 |
The apparatus and method described herein detect fluorescence polarization (FP) during a nucleic acid reaction such as PCR amplification or isothermal amplification. Fluorescence polarization can be concurrently detected in multiple samp...
|
|
WO/2003/099342A1 |
Radiolabeled adenosine or radiolabeled adenosine containing molecules for use in positron emission tomography for assessing alterations in adenylate metabolism in a patient are provided.
|
|
WO/2003/095608A2 |
Methods are disclosed for the construction of and interrogation of DNA arrays containing Active Chromatin Elements, and, thereby active genetic regulatory sequences.. Further methods are disclosed for interrogation of such arrays in orde...
|
|
WO/2003/095467A1 |
The invention relates to a novel strategy for the synthesis of Locked Nucleic Acid derivatives, such as &agr -L-oxy-LNA, amino-LNA, &agr -L-amino-LNA, thio-LNA, &agr -L-thio-LNA, seleno-LNA and methylene LNA, which provides scalable high...
|
|
WO/2003/095436A1 |
This invention relates to benzoisoselenazole derivatives of following formula (I), (II) and (III), and their pharmaceutically acceptable salts. Said derivatives can be used in anti-inflammation, antivirus or anti-thrombosis.
|
|
WO/2003/095468A1 |
A compound of formula (I); that has the S-configuration at the 4'-position and wherein the bond between carbon atoms 22 and 23 is a single or a double bond; R1 is C1-C12alkyl, C3-C8cycloalkyl; or C2-C12alkenyl; R2 is H, or, for example, ...
|
|
WO/2003/093290A2 |
Disclosed are compounds, compositions and methods for treating hepatitis C virus infections.
|
|
WO/2003/091311A1 |
A polymer support is provided which comprises protected hydroxypolyC2-4 alkyleneoxy chains attached to a cross-linked polymer wherein the protected hydroxypolyC2-4 alkyleneoxy chain contains from 2 to 10 C2-4 alkyleneoxy groups and where...
|
|
WO/2003/091267A1 |
A process for the preparation of an oligonucleotide is provided. The process comprises the assembly of an oligonucleotide attached to a solid support, wherein the solid support is prepared by a process comprising polymerisation of a mono...
|
|
WO/2003/089448A1 |
The invention relates to ibuprofen ribavirin ester, its method of preparation and use. The said ibuprofen ribavirin ester is used in antiphlogistic, antipyretic, antalgic and antiviral treatment. The invention also relates to the pharmac...
|
|
WO/2003/088978A1 |
ABSTRACT Methods are provided for treating arrhythmia in a manner that minimizes undesirable side effects, comprising administration of a therapeutically effective minimal dose of an A1 adenosine receptor agonist with a therapeutically e...
|
|
WO/2003/089670A2 |
Described herein are novel indicator molecules of general formula (I): wherein Q, F ,N, Nuc, X1 and X2 are as defined herein, including their tautomeric forms and their additive salts. The present invention also concerns methods for the ...
|
|
WO/2003/087130A2 |
A scalable process for purification of phosphorodiamidite includes steps of solubilizing a crude phosphorodiamidite in an apolar organic solvent, contacting the non-polar organic solvent with a polar phase comprising a polar organic solv...
|
|
WO/2003/087053A2 |
Silylating reagents having a group other than divalent oxygen separating two silyl groups provide regioselective protection of reactive groups under robust conditions, such as basic conditions used in alkylation, acylation and deoxygenat...
|
|
WO/2003/087119A1 |
The invention provided a method of synthesizing β -L-5-fluoro-2´,3´-dideoxy-2´,3´-didehydrocytidine (β -L-FD4C). The method allows for large-scale production of β -L-FD4C in an efficient, cost-efficient, and environmentally sound ...
|
|
WO/2003/086408A1 |
The present invention provides a therapeutic method for treating biological diseases that includes the administration of an effective amount of a suitable antibiotic agent, antifungal agent or antiviral agent in conjunction with A2A aden...
|
|
WO/2003/087118A2 |
The invention relates to a novel method, essentially having four stages, for producing beta-L-2'-deoxy-thymidine with L-arabinose as the starting material. The inventive method is particularly useful for the large-scale production of bet...
|
|
WO/2003/087765A2 |
The present invention is concerned with a genetic testing system that ensures complete traceability of animals and food products and involves a method of uniquely identifying animals for data collection, records management and retrieval ...
|
|
WO/2003/084975A1 |
This invention relates to new analogs or derivatives of nitrobenzylthioinosine, use of these new analogs of nitrobenzylthioinosine for the treatment of pain and various other diseases as well as pharmaceuticals comprising at least on new...
|
|
WO/2003/082890A1 |
The present invention related to a novel diastereoselective proces for preparing β-D- and β-L-2' , 3' -dideoxy nucleoside analogs and to intermediates useful in this process.
|
|
WO/2003/080620A1 |
The present invention relates to compounds of the general formula (I) which are inhibitors of 5'-methylthioadenosine phosphorylases and 5'-methylthioadenosine nucleosidases (MTAP and MTAN), the invention also relates to the use of these ...
|
|
WO2002018404A9 |
Use of compounds of formula (I), wherein R<1> is hydrogen, hydroxy, alkyl, hydroxyalkyl, alkoxy, halogen, cyano, isocyano or azido; R<2> is hydrogen, hydroxy, alkoxy, chlorine, bromine or iodine; R<3> is hydrogen; or R<2> and R<3> togeth...
|
|
WO/2003/080649A2 |
The present invention provides methods of inducing proliferative and differentiative mammalian hepatocytes, or survival of differentiative mammalian hepatocytes, in vitro comprising contacting the hepatocytes with protein kinase A (PKA) ...
|
|
WO/2003/078447A1 |
A nucleic acid base for hole transportation in DNAs which does not cause oxidative decomposition&semi and an artificial DNA molecule which can realize effective hole transportation in DNAs while maintaining the double spiral structure of...
|
|
WO/2003/077215A2 |
A fluorescent nitrogenous base and nucleosides including the fluorescent nitrogenous base are provided. Nucleosides including the fluorescent nitrogenous base are capable of Watson-Crick base pairing with naturally occurring nucleosides....
|
|
WO/2003/073989A2 |
The present invention relates to novel nucleoside 5'-monophosphate mimics, which contain novel nucleoside bases and phosphate moiety mimics optionally having sugar-modifications. The nucleotide mimics of the present invention, in a form ...
|
|
WO/2003/074541A1 |
An in situ process for preparing chloroadenosine is described, wherein adenosine in a non-aqueous solvent is reacted with a thionyl chloride and a pyridine to form a reaction solution; the non-aqueous solvent is exchanged with a lower al...
|
|
WO/2003/072066A2 |
The present invention is directed to a method of reducing intraocular pressure.The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a nucleoside 5'-pyrophosphate pyranoside oranal...
|
|
WO/2003/072067A2 |
The present invention relates to mononucleoside phosphate compoundsthat have the benefits of a dinucleotide pharmaceutical. These mononucleoside phosphates can be made from a mononucleotide that has been modified byattaching a degradatio...
|
|
WO/2003/070739A1 |
Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, myocardial infarction and hyperlipidemia.
|
|
WO2003051881B1 |
Nucleoside analog libraries are prepared in a combinatorial library approach. In some preferred aspects, library diversity is generated using solid phase-coupled nucleosides in a series of at least two modification reactions, and contemp...
|
|
WO/2003/070174A2 |
This invention features a compound of the following formula T-(-L-C)m, wherein T is a transportophore (a transport mediating molecule), L is a a non-antibiotic therapeutic agent, and m is l- 8, in which the transportophore has an immune ...
|
|
WO/2003/068795A1 |
A compound represented by the general formula (1) and a salt thereof: (1) wherein A represents a direct bond, C1-4 alkylene, etc.; B represents an optionally substituted aromatic heterocyclic group, etc.; and R1, R2, R3, and R4 each repr...
|
|
WO/2003/068162A2 |
The invention is a compound, composition, use for and a method of treating Flaviviridae (Hepacivirus, Flavirius, Pestivirus) infections, including BVDV and HCV, or abnormal cellular proliferation, including malignant tumors, in a host in...
|
|
WO/2003/068164A2 |
A dosage regiment for the treatment of a Flaviviridae infection, including a hepatitis C viral infection, that includes administering gemcitabine (or its salt, prodrug or derivative, as described herein) in a dosage range of approximatel...
|
|
WO2003051897B1 |
Nucleoside analog libraries are prepared in a combinatorial library approach. In some preferred aspects, diverse heterocyclic bases and/or diverse nucleoside substituents are prepared using solid phase-coupled nucleosides in a series of ...
|
|
WO/2003/068244A1 |
The present invention provides methods of inhibiting orthopoxvirus replication and&sol or treating orthopoxvirus infection with certain nucleoside compounds and derivatives thereof. These compounds are particularly useful as inhibitors o...
|
|
WO2002008446A9 |
The present invention provides for compositions and methods to generate a library of small molecules that mimic the repertoire of interactions that exist amongst nucleic acids, and proteins, as well as, that which exist between proteins ...
|
|
WO/2003/068794A1 |
Compounds represented by the general formula (1) and salts thereof: (1) wherein A is alkylene having 1 to 2 carbon atoms or the like; B is an optionally substituted aromatic heterocyclic group or the like; R1 and R2 are each hydrogen, a ...
|
|
WO/2003/068796A1 |
4’-C-Cyano-2’-deoxypurine nucleosides represented by the following general formula [I] which have an excellent anti-HIV effect, in particular, an efficacy on multidrug-resistant HIV strains having resistance to a plural number of ant...
|
|
WO/2003/066878A2 |
Provided herein are methods of producing duplicates of nucleic acid samples, such as Northern blots, Southern blots, and sequencing gels, and methods of analyzing nucleic acids on such duplicates. Also provided are kits for using in prod...
|
|
WO/2003/066633A1 |
This invention is directed to novel pyranosyl cytosine compounds depicted graphically as structure I. This invention is further directed to a unique methodology for their preparation using solid-phase methodology. These hexopyranosyl cyt...
|
|
WO/2003/066645A2 |
A compound of formula: in which R = OH or mono-, di- or triphosphate, R'= OH or H, R' = OH or H, L1 and L2, which can be the same or different, are each a linker comprised of A-B-C, wherein A = -(CH2)n, wherein n = 1-6 or -(CH=CH)-, B = ...
|
|
WO/2003/064625A2 |
The oligonucleotide compositions of the present invention make use of combinations of oligonucleotides. In one aspect, the invention features an oligonucleotide composition including at least 2 different oligonucleotides targeted to a ta...
|
|
WO/2003/063771A2 |
The present invention is directed to a method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animals hosts,...
|
|
WO/2003/064626A2 |
Antisense sequences, including duplex RNAi compositions, which possess improved properties over those taught in the prior art are disclosed. The invention provides optimized antisense oligomer compositions and method for making and using...
|
|
WO/2003/062257A1 |
Methods, compositions, and uses for various nucleoside analog libraries and library compounds are provided. Particularly preferred nucleosides include 6−C−purine nucleosides, 7,8−substituted purine nucleosides, pyrazolopyrimidine n...
|
|
WO/2003/061670A1 |
Adenosine analogue−type A3 receptor agonists having an N6 nitrogen substituted by a group which is usually −CH2−CYCLE, where CYCLE is a specified heteroaromatic group, particularly a pyrridyl or a bicyclic group, for example benzox...
|
|
WO/2003/062256A1 |
Various 2'-beta-methyl-6-substituted adenosine analogs (including 2,6-disubstituted adenosine, 8-aza-6-substituted adenosine, and 2-aza-6-substituted adenosine) are prepared by conventional and combinatorial library approaches. Contempla...
|
|
WO/2003/062255A2 |
Various 2'-modified nucleoside analogs and corresponding prodrugs are provided, and particularly contemplated methods of use include use as antiviral agents, and especially as antiviral agents against HCV.
|
